BRAF Inhibitor Compound Ia CAS No.:2649372-20-1

Introduction:

Hello and welcome to our product introduction for the BRAF Inhibitor Compound Ia CAS No.:2649372-20-1. We are a leading manufacturer located in China, and we specialize in producing and exporting high-quality pharmaceutical products to merchants around the world. Our BRAF Inhibitor Compound Ia is a highly-effective cancer drug that has been shown to provide exceptional results for patients diagnosed with various cancer types, including melanoma, breast cancer, lung cancer, and more. This product is backed by extensive research and clinical trials, and it has been approved by regulatory agencies in multiple countries as a highly-effective and safe medication.

What is BRAF Inhibitor Compound Ia?

The BRAF Inhibitor Compound Ia is a highly-selective BRAF inhibitor that targets and blocks the activity of the BRAF protein kinase, which controls the signaling pathways inside cancer cells. The BRAF protein is essential for the growth and survival of cancerous cells, and by inhibiting this protein, we can effectively reduce the cancer's ability to grow, divide, and spread. BRAF Inhibitor Compound Ia has proven to be highly effective in treating BRAF-mutated cancers by reducing tumor size and improving the overall survival rates of patients.

Key Features and Benefits:

- High Selectivity: BRAF Inhibitor Compound Ia is highly selective for BRAF proteins, which means it targets and blocks only the cancerous cells, which reduces the risk of negative side effects on healthy cells.

- Superior Efficacy: Our product has been proven to be highly effective in treating different types of cancers, including melanoma, breast cancer, lung cancer, and more. Several clinical trials have shown a significant reduction in the size of tumors, improvement in disease-free survival, and a reduction in the overall risk of the disease progressing.

- Improved Patient Outcomes: With BRAF Inhibitor Compound Ia, patients diagnosed with BRAF-mutated cancers have a higher chance of survival, better quality of life, and reduced symptoms.

- Safe and Tolerable: Our product has undergone extensive testing and trials, and it has been recognized as a safe and well-tolerated medication. We adhere to strict quality standards during the manufacturing process to ensure the highest level of safety and effectiveness for our customers.

- Easy to Administer: BRAF Inhibitor Compound Ia is available in oral tablets, making it easy and convenient for patients to take at home.

Conclusion:

In conclusion, the BRAF Inhibitor Compound Ia CAS No.:2649372-20-1 is a highly-effective cancer medication with several key features and benefits. As a manufacturer, we take pride in producing high-quality products using state-of-the-art technology and adhering to strict quality standards. Our BRAF Inhibitor Compound Ia has undergone extensive clinical trials and has been approved by regulatory agencies worldwide. We believe that our product can offer significant benefits to patients diagnosed with BRAF-mutated cancers and provide an excellent opportunity for merchants to provide meaningful support that can benefit their customers. Thank you for reading our product introduction, and we look forward to working with you.

Chemical Structure: BRAF inhibitor Compound Ia

CAS No.: 2649372-20-1

 

BRAF inhibitor Compound Ia

Catalog No.: URK-V2346 Only Used For Lab.

BRAF inhibitor Compound Ia is a potent, selective, brain penetrant BRAF inhibitor with binding Kd of 0.6, 1.2, and 1.7 nM for BRAF WT, BRAF V600E, and c-RAF, presenting paradox breaker properties.

Biological Activity

BRAF inhibitor Compound Ia is a potent, selective, brain penetrant BRAF inhibitor with binding Kd of 0.6, 1.2, and 1.7 nM for BRAF WT, BRAF V600E, and c-RAF, presenting paradox breaker properties. Compound Ia displays high selectivity profile conducted on 403 kinases with only one exception for the binding to the kinase BRK (Kd=156 nM). Compound Ia demonstrated potent kinase inhibitory activity across all BRAF mutants with IC50 values of <1.77 nM, including the clinical relevant BRAF mutants V600E/K/A/D.
Compound Ia was designed to avoid paradoxical MAPK hyperactivation in non-BRAF V600E models, an undesired property of the three currently approved BRAFi.

Physicochemical Properties

References

1. Wichmann J, et al. Clin Cancer Res. 2022 Feb 15;28(4):770-780.

URK-V2346_COA

URK-V2346_SDS

URK-V2346_TDS

 

Note: All products of Ureiko are only used for scientific research or drug certificate declaration, and we do not provide products and services for any personal use!

Why choose us?

• We take great pride in our ability to deliver top-quality Ras-Raf-MAPK-ERK Pathway Library products and services at an affordable price.
• All products of our company adopt international popular design and have our own professional design team with excellent quality.
• We are committed to providing our customers with the best possible Ras-Raf-MAPK-ERK Pathway Library products and services.
• We firmly believe that with our rich experience and unremitting pursuit of innovation and development, we will be able to provide customers with better products and services.
• Our company is known for its commitment to innovation and excellence in the field of Ras-Raf-MAPK-ERK Pathway Library products and services.
• Our company employs a team of professional technicians to ensure the quality advantage and rapid upgrading of BRAF Inhibitor Compound Ia CAS No.:2649372-20-1.
• We are passionate about providing our customers with the most comprehensive and innovative Ras-Raf-MAPK-ERK Pathway Library products and services available.
• We are dedicated, lean, focused and innovative with the spirit of craftsmanship to build excellent BRAF Inhibitor Compound Ia CAS No.:2649372-20-1, and rigorous specifications to strengthen the standard delivery and operation and maintenance capabilities.
• We are a Chinese factory with a range of high-quality Ras-Raf-MAPK-ERK Pathway Library products and professional services.
• We pay close attention to the needs of the market and pursue perfection.

Hot Tags: braf inhibitor compound ia cas no.:2649372-20-1, China braf inhibitor compound ia cas no.:2649372-20-1, epigenetic library for epigenetic analysis of epigenetic stability, inhibitors for scar formation, agonists for pharmacodynamics, epigenetic library for epigenetic analysis of epigenetic dysregulation, inhibitors for metabolic disorders, epigenetic library for epigenetic regulation of gene expression